Analysts See $-0.01 EPS for ProMIS Neurosciences Inc. (PMN)

March 1, 2018 - By Winifred Garcia

 Analysts See $ 0.01 EPS for ProMIS Neurosciences Inc. (PMN)

Analysts expect ProMIS Neurosciences Inc. (TSE:PMN) to report $-0.01 EPS on March, 21.They anticipate $0.00 EPS change or 0.00 % from last quarter’s $-0.01 EPS. After having $-0.01 EPS previously, ProMIS Neurosciences Inc.’s analysts see 0.00 % EPS growth. The stock 1.23% or $0 during the last trading session, reaching $0.4. It is down 0.00% since March 1, 2017 and is . It has underperformed by 16.70% the S&P500.

ProMIS Neurosciences Inc., a development stage biotech company, discovers and develops precision medicine therapeutics for treatment of neurodegenerative diseases, primarily Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The company has market cap of $88.02 million. The Company’s proprietary target discovery engine is based on the use of two complementary techniques. It currently has negative earnings. The firm applies its thermodynamic, computational discovery platform?ProMIS and Collective Coordinates to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins.

More recent ProMIS Neurosciences Inc. (TSE:PMN) news were published by: which released: “ProMIS Neurosciences Inc.” on October 18, 2016. Also published the news titled: “ProMIS Neurosciences Completes First Closing of Private Placement” on August 09, 2017.‘s news article titled: “BRIEF-Promis Neurosciences reports q1 2017 annual results” with publication date: May 09, 2017 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: